Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating

On Tuesday, Danaher Corp DHR reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. Guidance: Danaher reaffirms that in fiscal year 2024, non-GAAP core revenue will be down in the low single digits year over year. The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around $1.7 billion compared to prior guidance of $1.6 billion. William Blair reports that Danaher's ...